Saint-Antoine Hospital and University Pierre et Marie Curie VI, Paris, France.
Crit Rev Oncol Hematol. 2011 Dec;80(3):369-79. doi: 10.1016/j.critrevonc.2011.01.009. Epub 2011 Feb 16.
Molecular targeted therapies (MTTs) have become a major component of modern management of various hematological and solid malignancies. However, some MTTs have been associated with cardiotoxicity. MTT-induced cardiovascular side effects include left ventricular systolic dysfunction, heart failure, conduction abnormalities, acute coronary syndrome, and hypertension. One of the most threatening complications of MTT, and notably of angiogenic inhibitors, is QT prolongation with the risk of torsades de pointe and sudden death. The precise incidence of cardiovascular events associated with MTT as well as their reversibility are unknown. Here, we summarize what is known about the cardiotoxicity of MTT, emphasizing MTTs that target tyrosine kinases. We have tried to provide both the basic mechanisms underlying specific cardiotoxicities (such as the interruption of specific signaling pathways leading to cardiomyocyte dysfunction and/or death), and offer guidance regarding the optimal way to detect and treat these cardiotoxicities.
分子靶向治疗（MTT）已成为各种血液系统恶性肿瘤和实体瘤现代治疗的主要组成部分。然而，一些 MTT 与心脏毒性有关。MTT 引起的心血管副作用包括左心室收缩功能障碍、心力衰竭、传导异常、急性冠状动脉综合征和高血压。MTT 最具威胁性的并发症之一，特别是血管生成抑制剂，是 QT 延长伴尖端扭转型室性心动过速和猝死的风险。与 MTT 相关的心血管事件的准确发生率及其可逆转性尚不清楚。在这里，我们总结了 MTT 的心脏毒性，重点介绍了靶向酪氨酸激酶的 MTT。我们试图提供导致心肌细胞功能障碍和/或死亡的特定心脏毒性的基本机制，并就如何最佳地检测和治疗这些心脏毒性提供指导。
